

BAB 7

SIMPULAN DAN SARAN

7.1 Kesimpulan

Berdasarkan penelitian perbedaan kadar hemoglobin terglikasi (HbA1c) pada pasien kusta dan non kusta di dua fasilitas kesehatan Jawa Timur yaitu di RSUD Sumberglagah dan Puskesmas Bangkalan pada 36 responden penelitian yang dilaksanakan pada tanggal 9 September – 30 Oktober 2023, dapat disimpulkan sebagai berikut:

1. Berdasarkan karakteristik usia responden, baik pada responden pasien kusta dan non kusta didapatkan hasil mayoritas pada usia 26-35 tahun.
2. Berdasarkan karakteristik jenis kelamin, baik pada responden pasien kusta dan non kusta

didapatkan hasilnya mayoritas pada kelompok berjenis kelamin laki-laki

3. Berdasarkan uji statistik menggunakan uji *Mann-Whitney*, didapatkan hasil $P=0,375$ ($P>0,05$) yang menunjukkan bahwa tidak terdapat perbedaan kadar hemoglobin terglikasi (HbA1c) pada pasien kusta dan non kusta di dua fasilitas kesehatan Jawa Timur. Pada penelitian ini, pasien kusta dan non kusta mayoritas memiliki kadar HbA1c normal ($<5,7\%$).

7.2 Saran

7.2.1 Bagi Responden

Dengan dilakukannya penelitian ini, diharapkan responden pasien kusta maupun non kusta dapat lebih memperhatikan keadaan kadar gula darah dan dapat

melakukan kontrol gula darah melalui pemeriksaan HbA1c.

7.2.2 Bagi Peneliti Selanjutnya

Dengan dilakukannya penelitian ini, diharapkan bagi peneliti selanjutnya dapat menambahkan jumlah sampel yang lebih besar dari penelitian ini serta memperhatikan faktor-faktor lainnya yang dapat mempengaruhi kadar hemoglobin terglykasi (HbA1c)

7.2.3 Bagi Universitas Katolik Widya Mandala Surabaya

Dengan dilakukannya penelitian ini, diharapkan dapat dijadikan acuan untuk penelitian selanjutnya dan dapat memberikan informasi mengenai perbedaan kadar hemoglobin terglykasi (HbA1c) pada pasien kusta dan non kusta.

DAFTAR PUSTAKA

1. World Health Organization. Leprosy. 2023; Available from: <https://www.who.int/news-room/fact-sheets/detail/leprosy>
2. Kementerian Kesehatan Republik Indonesia. Menuju Eliminasi 2024, Kemenkes Ajak Masyarakat Hapus Stigma Dan Diskriminasi Kusta. 2022;
3. Dinkes Jatim. Profil Kesehatan Dinas Kesehatan Provinsi Jawa Timur 2021. Dinas Kesehat Provinsi Jawa Timur [Internet]. 2021;1–149. Available from: [https://dinkes.jatimprov.go.id/userfile/dokumen/Profil Kesehatan 2021 Jatim.pdf](https://dinkes.jatimprov.go.id/userfile/dokumen/Profil%20Kesehatan%2021%20Jatim.pdf)
4. Dinas Kominfo Provinsi Jawa Timur. Miliki Penderita Kusta Terbanyak, Masyarakat Diminta Lakukan Deteksi Dini. 2020; Available from: <https://kominfo.jatimprov.go.id/read/umum/miliki-penderita-kusta-terbanyak-masyarakat-diminta-lakukan-deteksi-dini>
5. Kementerian Kesehatan Republik Indonesia. Mengenal Kusta. 2022; Available from: https://yan.kes.kemkes.go.id/view_artikel/142/mengenal-kusta
6. Miller K. Leprosy (Hansen’s Disease). 2022;1–4. Available from: <https://www.webmd.com/skin-problems-and-treatments/guide/leprosy-symptoms-treatments-history>
7. Bhandari, Jenish; Awais, Mashal; Robbins BA. Leprosy. In StatPearls Publishing; 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559307/>

8. Centers of Disease Control and Prevention. Hansen's Disease (Leprosy). 2017; Available from: <https://www.cdc.gov/leprosy/transmission/index.html>
9. Saraya MA, Al-Fadhli MA, Qasem JA. Diabetic status of patients with leprosy in Kuwait. *J Infect Public Health* [Internet]. 2012;5(5):360–5. Available from: <http://dx.doi.org/10.1016/j.jiph.2012.08.001>
10. Sheilaadji MU, Listiawan MY, Ervianti E. Hubungan kadar antioksidan superoxide dismutase (SOD) dengan indeks bakterial (IB) pada pasien kusta baru tipe Multibasiler (MB) tanpada reaksi. *Berk Ilmu Kesehat Kulit dan Kelamin*. 2019;31(3):200–9.
11. Prawitasari DS. Diabetes Melitus dan Antioksidan. *KELUWIH J Kesehat dan Kedokt*. 2019;1(1):48–52.
12. Hurrle S, Hsu WH. The etiology of oxidative stress in insulin resistance. *Biomed J* [Internet]. 2017;40(5):257–62. Available from: <https://doi.org/10.1016/j.bj.2017.06.007>
13. Kemenkes RI. Hapuskan Stigma dan Diskriminasi terhadap Kusta. *InfoDatin Pusat Data dan Informasi Kementerian Kesehatan RI*. 2018. p. 1–11.
14. Menaldi, Sri Linuwih SW; Bramono, Kusmarinah; Indriatmi W. *Ilmu Penyakit Kulit dan Kelamin*. 7th ed. Jakarta: Badan Penerbit FKUI; 2019. 88 p.
15. Prakoeswa FRS. *Buku Ajar Kusta*. Hernawan, Budi; Prakoeswa CRS, editor. Muhammadiyah University Press; 2018.
16. Yusuf, Zuhriana K.; Paramata, Nanang R.; Dulahu WY. *Kupas Tuntas Penyakit Kusta* [Internet].

- Mirnawati M, editor. Vol. 18, American Journal of Clinical Dermatology. Gorontalo: Ideas Publishing; 2018. Available from: <https://repository.ung.ac.id/get/karyailmiah/6639/Zuhriana-K-Yusuf-Kupas-Tuntas-Penyakit-Kusta.pdf>
17. Darmaputra IGN, Dewita Ganeswari PA. Peran sitokin dalam kerusakan saraf pada penyakit kusta: Tinjauan Pustaka. *Intisari Sains Medis* [Internet]. 2018;9(3):92–100. Available from: <https://www.isainsmedis.id/index.php/ism/article/viewFile/328/216>
 18. Chen KH, Lin CY, Su S Bin, Chen KT. Leprosy: A Review of Epidemiology, Clinical Diagnosis, and Management. *J Trop Med* [Internet]. 2022;2022:1–13. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273393/>
 19. Liwang, Ferry; Yuswar PW. WE, editor. *Kapita Selekta Jilid 2*. 5th ed. Depok: Media Aesculapius Fakultas Kedokteran Universitas Indonesia; 2020.
 20. Rathod SP, Jagati A, Chowdhary P. Disabilities in leprosy: an open, retrospective analyses of institutional records. *An Bras Dermatol* [Internet]. 2020;95(1):52–6. Available from: <https://doi.org/10.1016/j.abd.2019.07.001>
 21. Menteri Kesehatan Republik Indonesia. *Penganggulangan Kusta*. 2019;16–25. Available from: http://hukor.kemkes.go.id/uploads/produk_hukum/PMK_No__11_Th_2019_ttg_Penanggulangan_Kusta.pdf
 22. Brandsma JW, van Brakel WH. WHO Disability Grading. *Lepr Rev*. 2003;74:366–73.
 23. World Health Organization. *Guidelines for the diagnosis, treatment and prevention of leprosy* [Internet]. 2018. Available from: <https://apps.who>

- .int/iris/bitstream/handle/10665/274127/9789290227007-spa.pdf?sequence=37&isAllowed=y
24. Buku Ajar Ilmu Penyakit Dalam FKUI Jilid 2. 6th ed. Jakarta: Interna Publishing; 2014.
 25. Kumar, Bhushan; Uprety, Shraddha, Dogra S. The International Textbook of Leprosy [Internet]. Scollard, David M.; Gillis TP, editor. Vol. 104, Journal of the Indian Medical Association. India; 2006. 676–679 p. Available from: https://www.internationaltextbookofleprosy.org/sites/default/files/ITL_2_1_Final_1.pdf
 26. Van Veen NHJ, Nicholls PG, Smith WCS, Richardus JH. Corticosteroids for treating nerve damage in leprosy. *Cochrane Database Syst Rev*. 2016;2016(5).
 27. Papang R, John AS, Abraham S, Rao PSSS. A study of steroid-induced diabetes mellitus in leprosy. *Indian J Lepr*. 2009;81(3):125–9.
 28. Ghosh A. A Central India Perspective on Leprosy and Its Association with Diabetes Mellitus. *J Soc Heal Diabetes*. 2019;07(01):037–8.
 29. Alduaiji NM. Steroid Induced Diabetes. *Diabetes Obes Int J*. 2017;2(4):2–5.
 30. Siagian JN, Purwastyastuti, Instiaty, Menaldi SL. Analysis of therapeutic effectiveness and adverse effects of long-term corticosteroids among leprosy patients with reactions: A retrospective cohort study. *SAGE Open Med* [Internet]. 2022;10(4). Available from: <https://journals.sagepub.com/doi/full/10.1177/20503121221089448>
 31. Thomazelli JA. Impaired fasting glucose related to cumulative dose of prednisone in patients with leprosy reactions: a glucose monitoring and management protocol. 2023;1–9. Available from:

- https://www.researchgate.net/publication/373708391_Impaired_fasting_glucose_related_to_cumulative_dose_of_prednisone_in_patients_with_leprosy_reactions_a_glucose_monitoring_and_management_protocol
32. International Diabetes Federation. IDF Diabetes Atlas [Internet]. 10th ed. International Diabetes Federation, editor. Vol. 102, Diabetes Research and Clinical Practice. 2021. 12–18 p. Available from: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf
 33. World Health Organization. Diabetes. 2022; Available from: https://www.who.int/health-topics/diabetes#tab=tab_1
 34. World Health Organization. Diabetes. 2023; Available from: <https://www.who.int/news-room/fact-sheets/detail/diabetes>
 35. American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. *Diabetes Care* [Internet]. 2021;44:S 15–33. Available from: https://diabetesjournals.org/care/article/44/Supplement_1/S15/30859/2-Classification-and-Diagnosis-of-Diabetes
 36. Fargion S, Dongiovanni P, Guzzo A, Colombo S, Valenti L, Fracanzani AL. Insulin and Insulin Resistance. *Aliment Pharmacol Ther Suppl* [Internet]. 2005;22(2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1204764/>
 37. Susantiningih T. Obesitas Dan Stress Oksidatif. *J Kesehat Univ Lampung*. 2015;5(9):219–25.
 38. Arief H, Widodo MA. Peranan Stres Oksidatif pada Proses Penyembuhan Luka. *J Ilm Kedokt Wijaya Kusuma*. 2018;5(2):22.
 39. Hardy OT, Czech MP, Corvera S. What causes the

- insulin resistance underlying obesity? *Natl Libr Med* [Internet]. 2014; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038351/>
40. Sihombing JR, Margareta E. Analisa Kadar HbA1c Pada Penderita Diabetes Melitus Tipe 2 di RSU Martha Friska Multatuli. *Sari Mutiara* [Internet]. 2019;1–7. Available from: https://berkas.uhn.ac.id/jenny_sihombing/LB-4.pdf
 41. Sartika F, Hestiani N. Kadar HbA1c pada Pasien Wanita Penderita Diabetes Mellitus Tipe 2 di Rsd Dr. Doris Sylvanus Palangka Raya. *Borneo J Med Lab Technol* [Internet]. 2019;2(1). Available from: <https://journal.umpr.ac.id/index.php/bjmlt/article/download/1086/984>
 42. Beladina, Nadhila; Adisasmita A. Diabetic Status of People Affected by Leprosy in Donorojo Leprosy Recovered Village: A Cross Sectional Study. 2021;191–9. Available from: <https://ejournal2.undip.ac.id/index.php/jekk/article/view/9235/5266>
 43. Nigam P, Dayal SG, Srivastava P, Joshi LD, Goyal BM, Dutt B, et al. Diabetic status in leprosy. *Hansenol Int* [Internet]. 1979;4(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/261975/>
 44. Ganeswari PAD, Darmaputra IGN, Rusyati LMM. Kadar interleukin-10 serum yang tinggi berkorelasi dengan indeks bakteri yang tinggi pada penderita kusta tipe multibasiler. *Intisari Sains Medis* [Internet]. 2022;13(3):771–7. Available from: <https://isainsmedis.id/index.php/ism/article/view/1537/1151>
 45. Barnes PF, Chatterjee D, Brennan PJ, Rea TH, Modlin RL. Tumor necrosis factor production in

- patients with leprosy. *Infect Immun* [Internet]. 1992;60(4):1441–6. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC257016/pdf/iai00028-0191.pdf>
46. Notoatmodjo S. *Metodologo Penelitian Kesehatan*. 2012;144.
 47. Amaliah R, Yuniati L, Roem NR, Vitayani S, Setiawati S. Karakteristik Penderita Lepra (Kusta) yang Menjalani Pengobatan Rawat Jalan di Puskesmas Tamalate Makassar Periode 2018-2021. *Fakumi Med J* [Internet]. 2023;3(5):357–65. Available from: <https://fmj.fk.umi.ac.id/index.php/fmj/article/download/231/186/>
 48. Dewi MK. Distribusi spasial dan analisis trend penyakit kusta tiga tahun terakhir di Rumah Sakit Sumberglagah Provinsi Jawa Timur tahun 2019. *FKM Ahmad Dahlan Yogyakarta* [Internet]. 2019;1(1):3. Available from: <http://eprints.uad.ac.id/14965/>
 49. Qoyyum Nabila A, Adila Nurainiwati S, Handaja D. Profil Penderita Penyakit Kusta Di Rumah Sakit Kusta Kediri Periode Januari 2010 Sampai Desember 2010. *Saintika Med* [Internet]. 2017;8(2):70–7. Available from: <https://ejournal.umm.ac.id/index.php/sainmed/article/view/4106>
 50. Yang J, Li X, Sun Y, Zhang L, Jin G, Li G, et al. Global epidemiology of leprosy from 2010 to 2020: A systematic review and meta-analysis of the proportion of sex, type, grade 2 deformity and age. *Pathog Glob Health* [Internet]. 2022;116(8):467–76. Available from: <https://doi.org/10.1080/20477724.2022.2057722>
 51. Zuraida Z, Nurhidayah S. Prevalensi Pasien Baru Kusta Di RSUD Budhi Asih Tahun 2015 Sampai

- Tahun 2018. *Anakes J Ilm Anal Kesehat.* 2020;6(2):181–93.
52. Pranata M, Nugrahaini ARDN, Fajariah N. Characteristics and Therapy in Leprosy Patients at The Semarang City of Tugurejo Hospital. *Med Sains [Internet].* 2022;7(4):943–50. Available from: <https://ojs.stfmuhammadiyahcirebon.ac.id/index.php/iojs/article/view/460/371>
 53. Eyth E, Naik R. Hemoglobin A1C. 2023; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK549816/>
 54. Anggraini R, Nadatein I, Astuti P. Relationship of HbA1c with Fasting Blood Glucose on Diagnostic Values and Lifestyle in Type II Diabetes Mellitus Patients. *Medicra (Journal Med Lab Sci [Internet].* 2020;3(1):5–11. Available from: <https://medicra.umsida.ac.id/index.php/medicra/article/view/651/691>
 55. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. *Biomark Insights [Internet].* 2016;11:95–104. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933534/>
 56. Wibowo R, Nugraha G, Julianti Isma Sari. Description Of HbA1c Values and Fast Glucose In Diabetes Melitus Patients. 2019;1:5–8.
 57. Menaldi SLSW. Pedoman Nasional Pelayanan Kedokteran Tatalaksan. Kementerian Kesehat RI [Internet]. 2020;106. Available from: <https://kbbi.kemdikbud.go.id/entri/Tata Laksana>
 58. Danve AS, Kulkarni S. Do tumor necrosis factor (TNF) inhibitors improve the glycemic control in patients with rheumatoid arthritis and concomitant

- diabetes mellitus? *Am J Ther* [Internet]. 2017;24(3):e347–50. Available from: <https://pubmed.ncbi.nlm.nih.gov/26103543/>
59. Togashi N, Ura N, Higashiura K, Murakami H, Shimamoto K. Effect of TNF- α -converting enzyme inhibitor on insulin resistance in fructose-fed rats. *Hypertension* [Internet]. 2002;39(2 II):578–80. Available from: <https://www.ahajournals.org/doi/10.1161/hy0202.103290>
 60. Basavaraj GS, Gupta R Das, Patel B, Jebasingh F, George AA, Peter D, et al. Erroneous reduction of HbA1c levels in patients with type 2 diabetes mellitus on dapsone treatment for Hansen's disease - a single-center retrospective cohort study. *Indian J Dermatol Venereol Leprol* [Internet]. 2022;88(4):519–22. Available from: <https://ijdv1.com/erroneous-reduction-of-hba1c-levels-in-patients-with-type-2-diabetes-mellitus-on-dapsone-treatment-for-hansens-disease-a-single-center-retrospective-cohort-study/>
 61. Ram N, Rashid MO, Farooq S. Spuriously low HbA1C levels in a type II diabetes patient taking dapsone. *J Coll Physicians Surg Pakistan* [Internet]. 2017;27(4):262–262. Available from: https://ecommons.aku.edu/cgi/viewcontent.cgi?article=1057&context=pakistan_fhs_mc_med_diabet_endocrinol_metab
 62. Unnikrishnan R, Anjana R, Jayashri R, Mohan V. Unexpectedly low HbA1c levels in two diabetes patients following dapsone use. *Indian J Endocrinol Metab* [Internet]. 2012;16(4):658. Available from : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401779/>
 63. Shah AD, Fox RK, Rushakoff RJ. Falsely

decreased HbA 1c in a type 2 diabetic patient treated with dapsons. *Endocr Pract* [Internet]. 2014;20(11):e229–32. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423899/>

64. Lai YC, Wang CS, Wang YC, Hsu YL, Chuang LM. Falsely decreased HbA1c in a type 2 diabetic patient treated with dapsons. *J Formos Med Assoc* [Internet]. 2012;111(2):109–12. Available from: <http://dx.doi.org/10.1016/j.jfma.2012.01.007>
65. Rastogi A, Gahlot A, Agrawal N, Singh S. Artificially lowered glycosylated hemoglobin (HbA1c %) in patient with diabetes on dapsons. *Indian J Endocrinol Metab* [Internet]. 2012;16(4):657. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401778/>